Aquestive Drug Patent Portfolio
Aquestive owns 3 orange book drugs protected by 5 US patents Given below is the list of Aquestive's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273131 | Pharmaceutical compositions with enhanced permeation | 18 Jun, 2038 | Active |
| US9095577 | Stabilized amine-containing actives in oral film compositions | 13 Jul, 2030 | Active |
| US8580830 | Non-mucoadhesive film dosage forms | 23 Nov, 2029 | Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 03 Apr, 2024 | Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 20 Feb, 2024 | Expired |
Latest Legal Activities on Aquestive's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aquestive.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 27 Oct, 2021 | US8580830 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 27 Oct, 2021 | US8580830 |
|
Maintenance Fee Reminder Mailed
Critical
| 05 Jul, 2021 | US8580830 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Jun, 2021 | US8603514 (Litigated) |
|
Email Notification
Critical
| 07 Apr, 2021 | US8580830 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 07 Apr, 2021 | US8580830 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 06 Apr, 2021 | US8580830 |
|
Correspondence Address Change
Critical
| 05 Apr, 2021 | US8580830 |
|
Request for Trial Denied
Critical
| 20 Oct, 2017 | US8603514 (Litigated) |
| Termination or Final Written Decision | 06 Oct, 2017 | US8603514 (Litigated) |
| Petition Requesting Trial | 12 Jun, 2017 | US8603514 (Litigated) |
| Petition Requesting Trial | 09 Jun, 2017 | US8603514 (Litigated) |
|
Request for Trial Granted
Critical
| 12 May, 2017 | US8603514 (Litigated) |
|
Request for Trial Denied
Critical
| 05 Dec, 2016 | US8603514 (Litigated) |
| Petition Requesting Trial | 04 Nov, 2016 | US8603514 (Litigated) |
Aquestive's Drug Patent Litigations
Aquestive's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 28, 2014, against patent number US8765167. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with MonoSol Rx, LLC. as the respondent. Click below to track the latest information on how companies are challenging Aquestive's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | November, 2016 |
Terminated-Settled
(06 Oct, 2017)
| MonoSol Rx, LLC et al. | Mylan Technologies, Inc. et al. |
| US8603514 | May, 2016 |
Terminated-Denied
(05 Dec, 2016)
| MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | December, 2015 |
Terminated-Denied
(23 May, 2016)
| MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 |
FWD Entered
(24 Mar, 2016)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Settled
(24 Mar, 2016)
| MonoSol Rx, LLC. et al. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 |
Terminated-Denied
(20 May, 2015)
| MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
Aquestive's Family Patents
Aquestive Drug List
Given below is the complete list of Aquestive's drugs and the patents protecting them.
1. Exservan
Exservan is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
03 Apr, 2024
(7 months ago)
| Expired |
| US8765167 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
20 Feb, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Exservan's drug page
2. Libervant
Libervant is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273131 | Pharmaceutical compositions with enhanced permeation |
18 Jun, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Libervant's drug page
3. Zuplenz
Zuplenz is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9095577 | Stabilized amine-containing actives in oral film compositions |
13 Jul, 2030
(5 years from now)
| Active |
| US8580830 | Non-mucoadhesive film dosage forms |
23 Nov, 2029
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zuplenz's drug page